These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12810356)

  • 1. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).
    Brunet M; Campistol JM; Millán O; Vidal E; Esforzado N; Rojo I; Jiménez O; Oppenheimer F; Corbella J; Martorell J
    Int Immunopharmacol; 2003 Jul; 3(7):987-99. PubMed ID: 12810356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
    Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
    Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
    Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
    Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
    Lück R; Böger J; Kuse E; Klempnauer J; Nashan B
    Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for IFN-gamma up- and IL-4 downregulation late post-transplant in patients with good kidney graft outcome.
    Sadeghi M; Daniel V; Naujokat C; Schmidt J; Mehrabi A; Zeier M; Opelz G
    Clin Transplant; 2007; 21(4):449-59. PubMed ID: 17645703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S; Vareesangthip K; Ong-ajyooth L
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
    Ray JE; Keogh AM; McLachlan AJ
    J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
    Neumann I; Fuhrmann H; Kanzler M; Fang IF; Jaeger A; Graf H; Bayer P; Kovarik J
    Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P; Ortiz AM; Jara A; Vilches S
    Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH; Ko WJ; Chou NK; Wang SS
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations.
    Felipe CR; Silva HT; Machado PG; Garcia R; Moreira SR; Pestana JO
    Transpl Int; 2003 Jul; 16(7):494-503. PubMed ID: 12677364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus in pediatric de nova renal transplant patients.
    Hoyer PF; Ettenger R; Kovarik JM; Webb NJ; Lemire J; Mentser M; Mahan J; Loirat C; Niaudet P; VanDamme-Lombaerts R; Offner G; Wehr S; Moeller V; Mayer H;
    Transplantation; 2003 Jun; 75(12):2082-5. PubMed ID: 12829916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.